Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Tolerability Trial of Arimoclomol for Sporadic Inclusion Body Myositis

Trial Profile

Safety and Tolerability Trial of Arimoclomol for Sporadic Inclusion Body Myositis

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 11 Feb 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arimoclomol (Primary)
  • Indications Inclusion body myositis
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Feb 2020 Results published in the CytRx Corporation Media Release.
    • 05 May 2014 New trial record
    • 03 May 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top